LINC00930 and nasopharyngeal carcinoma: LINC00930 was first reported in nasopharyngeal carcinoma [17], where it binds the RBBP5 and GCN5 complexes to the PFKFB3 promoter, elevates H3K4 trimethylation and H3K9 acetylation levels, transactivating PFKFB3, thereby promoting glycolytic flux and cell cycle progression.